ArQule Will Use System Built With SignalGene for Its Own p38 Goals | GenomeWeb

NEW YORK, Feb. 21 - ArQule will apply the computational compound design system it co-designed with SignalGene to its own p38 MAP kinase drug-discovery program, the two companies said on Thursday.


Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.